A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Folinic acid (Primary) ; Pralatrexate (Primary) ; Cobalamin
- Indications Cutaneous T-cell lymphoma; Haematological malignancies; Peripheral T-cell lymphoma; Stomatitis
- Focus Therapeutic Use
- Sponsors Acrotech Biopharma; Spectrum Pharmaceuticals
- 26 Aug 2019 Status changed from active, no longer recruiting to completed.
- 30 Jul 2019 Planned End Date changed from 1 Dec 2018 to 1 Nov 2019.
- 30 Jul 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Nov 2019.